Penn Medicine Provider
Infectious Diseases
Jessie Torgersen, MD, MHS, MSCE
5.0
(43)
Accepting new patients
Sees patients age 18 and up
Penn Infectious Diseases Penn Presbyterian

About me

  • Director, Center for Viral Hepatitis, Penn Presbyterian Medical Center
  • Director, Hepatitis Linkage Team, Penn Medicine
  • Assistant Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Wayne State University School of Medicine
  • Residency: Emory University
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

43 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
absolutely amazing
January 2025
5.0
5.0
very nice
January 2025
5.0
5.0
she is a true professional in every sense of the word. kind and caring, also very easy to talk to
October 2024
5.0
5.0
the is very thorough in her analysis and presentation

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Torgersen is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Mehta SJ, Torgersen J, Small DS, Mallozzi CP, McGreevey III JD, Rareshide CAL, Evans CN, Epps M, Stabile D, Snider CK, Patel MS Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial , JAMA Network Open, 5(3): 2022,e222427


Torgersen J, Taddei TH, Lo Re V 3rd. Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?" , J Hepatol, 77(1): 2022,258-259


Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd; North American AIDS Cohort Collaboration on Research, Design of IeDEA Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America , Hepatology, 74(3): 2021,1190-1202


Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re III V Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation , J Hepatol, 75(6): 2021,1312-1322


Anand P, Wilson J, Carter B, Bronstein A, Schwartz A, Harrington B, Adams T, Saine ME, Norris A, Metzger D, Short WR, Torgersen J Clinic screening for adverse childhood experiences in people living with HIV to Improve Care Delivery , AIDS Care, 34(9): 2022,1094-1102


Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma , J Acquir Immune Defic Syndr, 85(5): 2020,530-534


Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, de Castilla DL, Finberg KW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Remdesivir for the Treatment of Covid-19 - Final Report , N Engl J Med, 383(19): 2020,1813-1826


Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re III V HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status , J Natl Cancer Inst, 112(7): 2020,747-755


Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V 3rd Differences in Pathology, Staging, and Treatment between HIV(+) and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma , Cancer Epidemiol Biomarkers Prev, 29(1): 2020,71-78


Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people , BMC Gastroenterol, 19(1): 2019,52